Drug profile · INN
irinotecan hydrochloride
IRINOTECAN HYDROCHLORIDE
irinotecan hydrochloride (IRINOTECAN HYDROCHLORIDE) is a dna topoisomerase i inhibitor. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.
Drug details — irinotecan hydrochloride
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 18
- Data quality
- 0.89
Quick answer
irinotecan hydrochloride (IRINOTECAN HYDROCHLORIDE) is a dna topoisomerase i inhibitor. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
DNA topoisomerase I inhibitor
Primary target: DNA topoisomerase 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is irinotecan hydrochloride?
irinotecan hydrochloride (IRINOTECAN HYDROCHLORIDE) is a dna topoisomerase i inhibitor. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for irinotecan hydrochloride?
IRINOTECAN HYDROCHLORIDE is a marketed brand name for irinotecan hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of irinotecan hydrochloride?
irinotecan hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.